RenovoRx Sees Surge in Adoption for its Targeted Cancer Therapy Device

MOUNTAIN VIEW, CA – February 27, 2026 – RenovoRx, Inc. (Nasdaq: RNXT) is experiencing a significant groundswell in commercial momentum for its innovative cancer treatment technology, marking a pivotal year for the life sciences company. The number of U.S. cancer centers either actively using or requesting access to its FDA-cleared RenovoCath® drug-delivery device has tripled over the past twelve months, signaling growing physician interest in a more targeted approach to fighting solid tumors.

According to a recent announcement, 12 U.S. cancer centers are now commercially utilizing the device, with a robust sales pipeline of 33 additional centers that have formally requested access. This expansion, which includes several high-volume National Cancer Institute-designated centers, suggests a potential inflection point for the company as it transitions from a primarily clinical-stage entity to a commercial enterprise. Since its initial FDA clearance in 2014, the device has been used in over 700 successful procedures, building a foundation of real-world evidence.

“With 12 commercial centers actively using RenovoCath, additional centers preparing to launch, and Phase III enrollment nearing completion, we believe we are well positioned heading into 2026,” said Shaun Bagai, RenovoRx’s Chief Executive Officer. “Year-over-year utilization growth has been compelling... Rising physician engagement and a deepening sales pipeline gives us confidence in expanding adoption and utilization of RenovoCath, resulting in the potential for revenue growth throughout 2026 and beyond.”

Precision Over Poison: A New Treatment Paradigm

At the heart of RenovoRx's strategy is the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the RenovoCath device. The technology aims to fundamentally reshape the treatment of difficult-to-treat solid tumors by addressing a long-standing challenge in oncology: maximizing a drug's impact on cancer cells while minimizing its toxic, often debilitating, effects on the rest of the body.

Traditional intravenous (IV) chemotherapy floods the entire body with powerful drugs, leading to well-known side effects like hair loss, nausea, and fatigue. The TAMP system offers a starkly different method. It employs a patented double-balloon catheter that is threaded through the vascular system to the artery feeding a specific tumor. Once in place, the balloons inflate to temporarily isolate that section of the artery, allowing for the direct, pressure-driven delivery of chemotherapy into the tissue surrounding the tumor.

This localized approach is designed to “bathe” the tumor in a high concentration of medication. Pre-clinical studies have indicated that this method can achieve up to a 100-fold increase in local drug concentration compared to IV delivery. This is particularly crucial for notoriously difficult tumors like locally advanced pancreatic cancer (LAPC), which are often surrounded by dense, scar-like tissue (stroma) with poor blood supply, a barrier that often limits the effectiveness of systemic therapies. By concentrating the therapy where it's needed most, RenovoRx aims to improve patient outcomes and significantly reduce systemic toxicity, offering what some clinicians describe as a more “humane” approach to cancer care.

The Clinical Gauntlet and Strategic Leadership

While the RenovoCath device is commercially available, the company is also advancing a promising drug-device combination product candidate, known as IAG, in its ongoing Phase III TIGeR-PaC clinical trial. The study evaluates the efficacy of intra-arterial gemcitabine delivered via RenovoCath for patients with LAPC. The trial has already passed two separate reviews by an independent Data Monitoring Committee, which recommended the study continue as planned based on promising interim data.

Enrollment for the 114-patient trial is expected to conclude in early 2026, though final data is not anticipated until 2027. Underscoring its potential, the IAG candidate has received Orphan Drug Designation from the FDA for both pancreatic cancer and bile duct cancer. This status provides incentives and seven years of market exclusivity upon potential approval, a significant advantage in the competitive oncology market.

To steer this next phase of growth, RenovoRx has strategically expanded the role of its founder, Dr. Ramtin Agah, appointing him to the additional position of Executive Chairman. An interventional cardiologist with deep knowledge of the TAMP platform he invented, Dr. Agah is tasked with leveraging his clinical expertise to accelerate physician engagement and drive broader market penetration.

“TAMP is at the core of RenovoRx’s strategy to redefine cancer treatment through precise targeted cancer drug-delivery that aims to minimize toxicity and improve patient outcomes,” said Dr. Agah. “It is at this exciting time that I want to dedicate more of my effort and passion to expanding usage of RenovoCath.”

Navigating the Financial and Competitive Landscape

This clinical and commercial momentum is beginning to translate to the company's balance sheet. RenovoRx began generating revenue from RenovoCath sales in late 2024 and reported approximately $900,000 in sales for the first nine months of 2025, supported by repeat purchase orders from satisfied medical centers. However, the company remains in its early growth phase, reporting a net loss of $2.9 million for the third quarter of 2025 as it invests in its sales team and ongoing research.

With $10.0 million in cash and equivalents as of September 30, 2025, RenovoRx states it has a cash runway sufficient to fund operations into mid-2026, covering the completion of TIGeR-PaC enrollment and continued commercialization efforts. The company's success will depend on its ability to effectively compete with other interventional oncology techniques like chemoembolization (TACE) and radioembolization (TARE), while proving its unique value proposition to hospitals and physicians.

As RenovoRx stands at this critical juncture, its progress represents more than just corporate milestones. The growing adoption of its TAMP therapy platform reflects a broader shift in oncology toward more precise, less toxic treatments. For patients battling some of the most challenging cancers, this focus on targeted delivery holds the promise of more effective therapies with a better quality of life.